Processa Pharmaceuticals, Inc. (PCSA) financial statements (2022 and earlier)
Company profile
| Business Address |
7380 COCA COLA DRIVE HANOVER, MD 21076 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 15,416 | 692 | 1,741 | 2,847 | 3 | 2 | ||
| Cash and cash equivalents | 15,416 | 692 | 1,741 | 2,847 | 3 | 2 | ||
| Receivables | 155 | 22 | 63 | |||||
| Prepaid expense | 258 | 41 | ||||||
| Disposal group, including discontinued operation | 12 | |||||||
| Assets held-for-sale, not part of disposal group | 42 | |||||||
| Other undisclosed current assets | 632 | 316 | 48 | |||||
| Total current assets: | 16,203 | 1,007 | 2,020 | 2,952 | 3 | 104 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 0 | 9 | 17 | 26 | 19 | 0 | ||
| Intangible assets, net (including goodwill) | 10,438 | |||||||
| Intangible assets, net (excluding goodwill) | 10,438 | |||||||
| Deposits noncurrent assets | 6 | |||||||
| Other noncurrent assets | 9,011 | 9,867 | 6 | |||||
| Other undisclosed noncurrent assets | (19) | |||||||
| Total noncurrent assets: | 9,012 | 9,876 | 10,461 | 31 | 0 | |||
| TOTAL ASSETS: | 25,214 | 10,883 | 12,481 | 2,983 | 3 | 104 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 546 | 311 | 416 | 151 | 742 | 416 | ||
| Accounts payable | 321 | 76 | 292 | 51 | 166 | 159 | ||
| Accrued liabilities | 225 | 213 | 103 | 64 | 135 | 95 | ||
| Taxes payable | 0 | 0 | ||||||
| Interest and dividends payable | 1 | 22 | 20 | 36 | 441 | 162 | ||
| Debt | 118 | 880 | 230 | 2,449 | 1,382 | 1,366 | ||
| Due to related parties | 70 | 0 | 0 | |||||
| Disposal group, including discontinued operation | 300 | |||||||
| Other undisclosed current liabilities | 487 | 230 | ||||||
| Total current liabilities: | 1,221 | 1,192 | 646 | 2,600 | 2,354 | 2,083 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 78 | 147 | ||||||
| Operating lease, liability | 78 | 147 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 531 | 1,532 | 2,134 | 10 | ||||
| Accounts payable and accrued liabilities | 10 | |||||||
| Deferred tax liabilities, net | ✕ | ✕ | 2,134 | |||||
| Deferred income tax liabilities | 531 | 1,532 | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | 445 | |||||||
| Total noncurrent liabilities: | 1,054 | 1,679 | 2,134 | 10 | ||||
| Total liabilities: | 2,275 | 2,871 | 2,780 | 2,610 | 2,354 | 2,083 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | 22,939 | 8,013 | 9,701 | 373 | (2,351) | (1,979) | ||
| Preferred stock | 0 | 0 | ||||||
| Common stock | 1 | 1 | 4 | 4 | 1 | 1 | ||
| Common stock, value, subscriptions | 1,800 | |||||||
| Additional paid in capital | 48,334 | 18,994 | 19,121 | 4,229 | 14,329 | 14,322 | ||
| Accumulated deficit | (25,396) | (10,982) | (7,624) | (3,859) | (15,255) | (14,875) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | (3,600) | (1,426) | (1,428) | ||||
| Total stockholders' equity: | 22,939 | 8,013 | 9,701 | 373 | (2,351) | (1,979) | ||
| TOTAL LIABILITIES AND EQUITY: | 25,214 | 10,883 | 12,481 | 2,983 | 3 | 104 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 5 | 5 | 113 | ||||
| Revenue, net | ✕ | ✕ | ✕ | 5 | 75 | ||
| Other income | 5 | ||||||
| Cost of revenue (Cost of Goods and Services Sold) | (126) | ||||||
| Gross profit: | 5 | 5 | (12) | ||||
| Operating expenses | (6,437) | (3,935) | (4,525) | (1,802) | (77) | (2,679) | |
| Other operating expense, net | (266) | (292) | |||||
| Other undisclosed operating loss | (8,700) | (5) | |||||
| Operating loss: | (15,137) | (3,935) | (4,525) | (1,802) | (337) | (2,983) | |
| Nonoperating income (Investment Income, Nonoperating) | 3 | 12 | 18 | 5 | 5 | ||
| Interest and debt expense | (281) | (37) | (161) | (59) | (241) | (236) | |
| Loss from continuing operations before equity method investments, income taxes: | (15,415) | (3,961) | (4,668) | (1,856) | (578) | (3,214) | |
| Other undisclosed income from continuing operations before income taxes | 241 | 231 | |||||
| Loss from continuing operations before income taxes: | (15,415) | (3,961) | (4,668) | (1,856) | (337) | (2,983) | |
| Income tax benefit | 1,001 | 603 | 903 | 0 | |||
| Loss from continuing operations: | (14,414) | (3,358) | (3,765) | (1,856) | (337) | (2,983) | |
| Income (loss) from discontinued operations | 1 | (371) | |||||
| Net loss: | (14,414) | (3,358) | (3,765) | (1,856) | (336) | (3,354) | |
| Net income (loss) attributable to noncontrolling interest | 43 | (43) | |||||
| Other undisclosed net income (loss) attributable to parent | (43) | 43 | |||||
| Net loss attributable to parent: | (14,414) | (3,358) | (3,765) | (1,856) | (336) | (3,354) | |
| Other undisclosed net loss available to common stockholders, basic | (56) | (507) | (43) | (43) | |||
| Net loss available to common stockholders, diluted: | (14,469) | (3,865) | (3,765) | (1,856) | (379) | (3,397) | |
Comprehensive Income ($ in thousands)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (14,414) | (3,358) | (3,765) | (1,856) | (336) | (3,354) | |
| Comprehensive loss, net of tax, attributable to parent: | (14,414) | (3,358) | (3,765) | (1,856) | (336) | (3,354) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.